Clinical Trial

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Study acronym: EPAG2015
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy. A phase II multicenter and randomized placebo-controlled study
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-07-26; most recent amendment 2024-10-25.
Status change: Recruiting → Active, Not Recruiting 2021-06-28
Status change: Not Yet Recruiting → Recruiting 2018-10-23
Trial Details
NCT Number NCT03603795
Lead Sponsor French Innovative Leukemia Organisation
Collaborators: Novartis Pharmaceuticals
Conditions Acute Myeloid Leukemia
Enrollment 110 participants
Start Date 2018-10-11
Primary Completion 2022-06-15 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-29